Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

In this study (n=345), carboplatin–pegylated liposomal doxorubicin–bevacizumab was associated with longer median progression-free survival than standard treatment (carboplatin–gemcitabine–bevacizumab; median 13.3 months vs. 11.6 months; HR 0.81; 95% CI 0.68–0.96; p=0.012).

SPS commentary:

A related Comment notes that no new safety signals were reported with the experimental group and that the overall effect of treatment on quality of life was similar; however the proportion of patients with fatal adverse events and grade 3-4 haematological toxicity, although low, was more common with the experimental treatment, and it requires visits to clinic every two weeks. The authors believe that carboplatin–pegylated liposomal doxorubicin–bevacizumab should be the new standard of care, however acknowledge that it was only able to delay recurrence by less than 3 months, and overall survival was improved by just over 4 months.


The Lancet Oncology

Resource links: